GLP-1 receptor agonists × cardiovascular events

TrialThe New England journal of medicine2016

Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.

Steven P Marso et al.PubMed ↗Publisher ↗

What the trial testedrandomised · 3,297 people · 2016

Randomised comparison

Reduced cardiovascular events

−39%−62% to −1%

Bigger than 8 in 10 for cardiovascular events

As reported

HR 0.61, 95% CI 0.38–0.99

Range includes no effect

No clear effect on cardiovascular events

−26%−49% to +8%

7 in 100 instead of 9

Bigger than 6 in 10 for cardiovascular events

As reported

HR 0.74, 95% CI 0.51–1.08

Not counted

Raised kidney outcomes

1.8×1.1× to 2.8×

Bigger than 8 in 10 on the map

As reported

HR 1.76, 95% CI 1.11–2.78

Three numbers in the abstract

the abstract, start to end

those receiving placebo (hazard ratio, 0.74; 95% CI, 0.51 to 1.08; P=0.12); nonfatal stroke occurred in 1.6% and 2.7%, respectively (hazard ratio, 0.61; 95% CI, 0.38 to 0.99; P=0.04).

were significantly higher (hazard ratio, 1.76; 95% CI, 1.11 to 2.78; P=0.02).

← favours treatmentfavours comparator →
could be chance
Cardiovascular events
HR 0.740.51–1.08
Cardiovascular events
HR 0.610.38–0.99
Kidney outcomes
HR 1.761.11–2.78
GLP-1 receptor agonistsCardiovascular eventsKidney outcomes

GLP-1 receptor agonists × cardiovascular eventshelps?mixed

unlikelylikely
0.500.50 without it
← favours treatmentfavours comparator →
this papermore certainless certain
1 / 6

2,804 papers cite itlatest 60 shown

2016
2026
this paperpooled ittrialcites it

16 trials

Full record →Abstract, authors, funding and every citing paper · PMID 27633186